Structural Heart Devices Market – By Product, By Procedure, By End Use - Global Forecast, 2025 - 2034

Structural Heart Devices Market Size

The global structural heart devices was valued at USD 12.3 billion in 2024 and is expected to reach USD 28.8 billion in 2034 with a CAGR of 8.8% from 2025 to 2034. The structural heart device market demonstrates significant growth driven by increasing cardiovascular diseases globally, expanded insurance coverage, and growing adoption of minimally invasive procedures.
 

The prevalence of cardiovascular diseases (CVD) continues to increase due to population aging, poor dietary habits, genetic predisposition, and chronic conditions. These factors frequently manifest in valve diseases, cardiomyopathy, and congenital heart defects. According to World Health Organization data, approximately 17.9 million people worldwide experienced cardiovascular diseases in 2021. Additionally, among 17 million premature deaths from noncommunicable diseases, cardiovascular diseases constituted 38%.
 

In developed nations, the aging population faces increased susceptibility to age-related cardiac conditions, particularly valve diseases. The prevalence of Coronary Heart Disease (CHD) increases with age, as evidenced by CDC statistics: 7.1% of adults aged 45-64 had CHD in 2019, increasing to 17% in individuals over 65. These demographics indicate substantial market potential for structural heart devices.
 

Structural heart devices enable specialized diagnostic and monitoring procedures for dangerous cardiac arrhythmias. These devices generate precise, real-time cardiac imaging and electrical activity mapping, allowing physicians to accurately identify arrhythmia sources.
 

Structural Heart Devices Market Trends

The development of highly efficient structural heart devices results from technological innovation. The replacement or repair of procedural devices is done more seamlessly because of these innovations.
 

• Less invasive heart procedures, such as transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve repair (TMVR), have changed the field of medicine dealing with the heart’s structure. There is less invasive surgery performed on the heart, which decreases the risks associated with open-heart surgery. For example, recovery is much faster after the procedure is done. In addition, there is much less risk associated with the procedure as well. A good example is the FDA approval granted in January 2023 for the Edwards Lifesciences PASCAL Precision Transcatheter Valve Repair System. TMVR procedures markedly lower mitral regurgitation (MR) symptoms and hospital stay in patients with moderate to severe MR who are considered either high or prohibitive surgical risk.
   
• Also, tremendous progress in other areas like transcatheter tricuspid valve replacement (TTVR) is changing the face of medicine dealing with heart valves. For instance, Abbott announced that the TriClip transcatheter tricuspid valve repair system had received a CE mark. This enables the use of the system in Europe. The TriClip device functions by means of a clip. A part of the tricuspid valve leaflets is clipped in the procedure.
   
• This disruptive technique minimizes the reflux of blood through the valve, which solves the problem of tricuspid regurgitation. With the development of the TTVR procedure, open-heart surgery is no longer a requirement. Instead, it uses a less invasive technique to mend the tricuspid valve, thereby lowering the invasiveness of the procedure and recovery periods.
   

Trump Administration Tariffs

• The U.S.-China trade tensions will likely impose future tariff policies, which may aggravate the price of imported parts and devices, in turn raising the cost of structural heart device systems, especially in the U.S. market.
   
• In order to sidestep some of these costs, manufacturers may shift production or assembly work to countries that do not impose tariffs. These moves might influence lead time along with overall product availability.
   
• Some of these costs could be transferred to the end users, making it more difficult for hospitals and ASCs to adhere to budgets, particularly in sensitive areas.
   
• In contrast, developed countries could stimulate local innovation and the manufacturing of mapping systems and components due to the lack of other options.
   

Structural Heart Devices Market Analysis

The global market was valued at USD 11.3 billion in 2023. Based on product, the market is classified into heart valve devices, annuloplasty rings, occluders and delivery systems, and other products. The heart valve devices segment generated the highest revenue of USD 5.1 billion in 2024.
 

• Calcific aortic valve disease and rheumatic heart disease are examples of conditions that have a considerable healthcare impact on a global scale. The CDC in the U.S. estimated in 2021 that approximately 2.5% of the population suffered from heart valve disease. In addition, heart valve diseases are responsible for almost twenty-five thousand deaths every year in the U.S. alone. These complications increase the need for efficient management and treatment, hence creating scope for greater utilization of heart valve devices in the market.
   
• Additionally, the market for advanced cardiovascular devices is supported by constant improvements made in heart valve technologies and non-invasive transcatheter heart valve replacement procedures, which are less invasive and more comfortable for patients. This is expected to greatly improve the growth of the market.
   

Based on procedure, the structural heart devices market is classified into replacement procedures and repair procedures. The replacement procedures segment held a dominant market share in 2024 and was valued at over USD 7.3 billion.
 

• The implementation of practices such as transcatheter heart valve replacement indicates a shift toward minimally invasive surgical techniques. These methods are preferred by patients because of their rapid recovery time.
   
• Moreover, the further development of heart surgery robotics that enable greater manipulation by the surgeon has completely altered the approach to replacements. The use of robotic arms for heart surgeries has improved precision, increasing the shift toward therapy replacements.
   
• Improvements in device design and procedural techniques have enabled the maximization of clinical results with replacement procedures. Consideration of safety, length of hospital stay, and quality of life for the patient further serves to strengthen the paradigm of prevalence around replacement procedures.
   

Based on end use, the structural heart devices market is segmented into hospitals, ambulatory surgical centers, cardiac catheterization labs, and other end uses. The hospitals segment dominated the market in 2024 and is anticipated to reach USD 5.2 billion by the end of the forecast period.
 

• Hospitals provide the full range of healthcare services and have implemented advanced techniques such as transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve repair (TMVR), which require specially tailored tools and more refined skill sets. These particular hospitals, especially those with specialized cardiac care units and interventional cardiology departments, are able to carry out these procedures. For instance, according to an article published by Cardiac Interventions Today, approximately half of structural heart clinics were within hospitals. The existence of sophisticated and modern cardiac prosthetic devices within hospital premises allows doctors to address intricate heart problems, thus improving their management and holistic care.
   
• Also, the needs of the growing population, coupled with the increasing burden of diseases, result in a high volume of patients. As the first contact for cardiovascular services, hospitals deal with a high volume of patients diagnosed with structural heart diseases, thus making them the principal consumers of structural heart devices.
   

 The U.S. structural heart devices market accounted for USD 3.8 billion in market revenue in 2024 and is anticipated to grow at a CAGR of 7.7% between 2025 to 2034.
 

• The U.S. captures most of the share in the market, which is supported by sophisticated healthcare infrastructure, adoption of medical technologies, and comprehensive procedures for structural heart conditions.
   
• The market is further fueled by leading device manufacturers and strong reimbursement policies offered for transcatheter and minimally invasive heart procedures.
   
• Increasing cases of aortic stenosis, along with the growing geriatric population base, are increasing the demand for transcatheter aortic valve replacement (TAVR) and other structural interventions.
   

In the Europe structural heart devices market, Germany is projected to grow remarkably in the coming years.
 

• Germany possesses the largest market share in Europe for structural heart devices due to the developed network of specialized cardiac centers and high procedural sophistication.
   
• Clinical innovation and excellence in the country promote the use of TAVR, TMVR, and LAAC. Germany is also a key growing contributor within the European structural heart landscape due to the aging population, along with favorable reimbursement policies.
   

In the Asia Pacific structural heart devices market, China is anticipated to witness robust growth over the forecast period.
 

• Growing understanding of cardiovascular health, expanding access to healthcare, and modernizing government initiatives towards cardiac care are what drive China to emerge as a high-growth market for structural heart devices.
   
• The growing number of cases of congenital heart conditions, as well as the adoption of transcatheter techniques in urban medical centers, is accelerating market adoption.
   
• Moreover, local and foreign device manufacturers are actively sponsoring clinical trials in China and partnering with local medical bodies, which is strategically good for business, considering the NMPA’s approval processes, resulting in the advancement of the market.
   

Structural Heart Devices Market Share

The market has a unique structure, where five major companies control about 75% of the market. These industry leaders include well-known names like Abbott, Medtronic, LivaNova, and Boston Scientific. In the market, each company is striving to enhance technology within their workflows, ensuring greater precision and efficiency in medical procedures. Recognizing the critical need for advanced real-time mapping during complex structural heart interventions, these organizations are dedicated to advancing patient care. To simplify procedures for healthcare professionals, they have introduced intuitive interfaces, ergonomically optimized designs, and streamlined workflows that significantly cut down the time required for each intervention, improving both outcomes and operational efficiency.
 

Structural Heart Devices Market Companies

Prominent players operating in the structural heart devices industry include:

• Abbott
• AtriCure
• BIOMERICS
• Boston Scientific
• BRAILE
• CryoLife
• Edwards
• JENAVALVE
• LEPU MEDICAL
• LivaNova
• Medtronic
• NUMED
   
• Abbott excels in delivering groundbreaking healthcare solutions across diagnostics, medical devices, nutrition, and pharmaceuticals, making it a versatile player in the industry. Abbott’s strategic focus on affordability, particularly in emerging markets, is notable. By investing heavily in research and development, Abbott continues to drive advancements in patient care while maintaining a strong commitment to improving lives worldwide.
   
• Medtronic stands out as a global leader in healthcare technology, offering innovative solutions across diverse medical fields such as cardiology, neurology, and diabetes care. With a focus on enhancing patient outcomes, the company is renowned for its minimally invasive technologies that aim to improve quality of life.
   

Structural Heart Devices Industry News:

• In September 2022, Medtronic announced the expanded U.S. market release of its newest-generation, self-expanding transcatheter aortic valve replacement (TAVR) system, the Evolut FX TAVR system. Evolut FX adds new features to the existing Evolut platform to enhance ease-of-use and predictable valve deployment for physicians. This product launch helped the company increase business revenue and acquire an enhanced customer base.
   
• In October 2021, Abbott announced the U.S. Food and Drug Administration (FDA) approval of two key minimally invasive devices, the Amplatzer Amulet Left Atrial Appendage (LAA) Occluder and the Portico with FlexNav transcatheter aortic valve replacement (TAVR) system. The Amulet device helps prevent blood clots and reduce stroke risk in people with atrial fibrillation (AFib). The Portico device helps open a narrowed aortic valve in people with aortic stenosis. This approval helped the company solidify its structural heart portfolio in the U.S.
   

The structural heart devices market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Heart valve devices
  • Surgical heart valves
  • Transcatheter heart valves
• Annuloplasty rings
• Occluders and delivery systems
• Other products

Market, By Procedure

• Replacement procedures
  • Surgical aortic valve replacement (SAVR)                    
  • Transcatheter aortic valve replacement (TAVR)                       
  • Transcatheter mitral valve replacement (TMVR)                      
  • Other replacement procedures
• Repair procedures   
  • Left atrial appendage closure (LAAC)       
  • Transcatheter mitral valve repair (TMVr)                      
  • Transcatheter tricuspid valve repair (TTVr)                   
  • Valvuloplasty          
  • Other repair procedures

Market, By End Use

• Hospitals
• Ambulatory surgical centers         
• Cardiac catheterization labs
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE